Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

The Trade Desks steep slide to multi-year lows is drawing attention amid concerns about weaker ad spending, slowing growth and competition from Amazon and other platforms. Traders are largely criticizing management and CEO compensation, while bullish voices argue the cash-rich company is oversold and could rebound; others expect more downside without evidence of a turnaround.

A pause in the federal cannabis-rescheduling hearing, with the judge asking the DEA to respond to a report on gaps in drug-scheduling procedures, has renewed uncertainty around the timing of a Schedule III recommendation. Traders are split between viewing the move as a limited procedural delay and worrying that it could prolong the process, with some calling the selloff an overreaction.

Iovances raised full-year revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, drove a sharp rally. Traders were broadly bullish and discussed a possible short squeeze and upcoming lung-cancer data, while others warned the run-up could invite profit-taking or share dilution.

The FHFAs move to include VantageScore alongside FICO in Fannie Mae and Freddie Mac mortgage pricing has raised concerns that competition could weaken FICOs longstanding mortgage-scoring advantage, driving a sharp selloff. Traders are divided between viewing the change as a serious threat to FICOs pricing power and moat, and arguing that the market is overreacting because FICO remains entrenched; many are also debating whether the drop is a buying opportunity or a falling knife.

AstraZenecas strategic investment and clinical collaboration around ivonescimab are driving attention, with traders welcoming the added financing and pharma validation while others weigh dilution and stress that the deal is not a buyout. Discussion also points to the upcoming FDA decision as a separate, uncertain catalyst.

Microns upcoming fiscal Q4 earnings and outlook are the main focus, with traders anticipating a strong report on tight DRAM and NAND supply and AI-driven memory demand. Bullish expectations are tempered by concern that much of the good news may be priced in and debate over how long the memory upcycle can last, leaving investors braced for volatility around the results.

A sharp pullback after a multiweek rally, despite traders pointing to recent share purchases by CEO Ryan Cohen, has sparked debate over profit-taking and options-related pressure versus alleged short-side manipulation. Bulls are buying the dip and speculating about a squeeze, while skeptics say the stock needs concrete company news.

Trulieves addition to the S&P Total Market and S&P Completion indices is driving attention, with traders viewing index-related demand as supportive and reacting bullishly. The optimism is tempered by profit-taking and uncertainty over the timing of the DEA judges recommendation on cannabis rescheduling.

DraftKings selloff is prompting debate over competition from Kalshi and Polymarket and the cost of building its own prediction-market business, DKeX. Bears worry the platforms are taking wagering share and that higher investment will weigh on margins; bulls point to DKeXs reported volume growth and argue DraftKings could benefit whether prediction markets expand or face tighter state regulation.

ICPs sharp rebound and push through a closely watched resistance area have sparked momentum trading, with traders debating whether the move can hold or will fade like prior rallies. Supporters point to the projects AI and decentralized-cloud ambitions and reported Pakistan deployments, while skeptics remain focused on its weak price history and selling pressure.